Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2020 | Key clinical trials in CLL at ASH 2020

Kerry Rogers • 1 Dec 2020

ASH 2020

Chronic Lymphocytic Leukemia Leukemia Antibodies Chlorambucil Obinutuzumab Pirtobrutinib Ublituximab Umbralisib

BRUIN UNITY-CLL

Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses highlights in the field of chronic lymphocytic leukemia (CLL) from ASH 2020, including the Phase III Unity-CLL study (NCT02612311) comparing umbralisib plus ublituximab to obinutuzumab plus chlorambucil in patients with treatment naïve and relapsed/refractory CLL, and the Phase I/II BRUIN study (NCT03740529) investigating the Bruton’s tyrosine kinase inhibitor LOXO-305 in CLL/small lymphocytic leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence

Kerry Rogers • 8 Dec 2023

The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL

Kerry Rogers • 8 Dec 2023

Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment

Kerry Rogers • 8 Dec 2023

Comorbidity and geriatric assessment tools in routine practice for CLL patients

Kerry Rogers • 7 Oct 2023

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024